New blood clot drug tested in humans for first time
NCT ID NCT06665828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety of a new drug called REGN9533 in 72 healthy adults. REGN9533 is a monoclonal antibody that blocks factor XII, a protein involved in blood clotting. The goal was to see if it is safe and how the body processes it, before testing it in people with blood clot disorders.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN9533 (a monoclonal antibody that blocks factor XII, a protein involved in blood clotting)
What this could lead to
If successful, this could lead to a new treatment to prevent dangerous blood clots (thromboembolic diseases) with potentially fewer bleeding risks than current options.
What could go wrong
This is a very early Phase 1 trial in only 72 healthy people, so it is not designed to prove effectiveness. The drug may cause unexpected side effects or fail in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium NV_Edegem
Edegem, Antwerp, 2650, Belgium